HIFU shows promise as salvage therapy post-XRT

October 15, 2004

Vaulx-en-Velin, France--High-intensity focused ultrasound (HIFU) appears to be a promising salvage therapy option in carefully selected recurrent prostate cancer patients who have previously undergone external beam radiation therapy. The device, which uses sound waves to target tumors, was found in a French study to stop disease progression in slightly more than 40% of patients at mean follow-up of 15 months.